Collegium Pharmaceutical, Inc.
COLL
$28.23
$0.080.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 808.21M | 796.33M | 780.57M | 757.07M | 707.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 808.21M | 796.33M | 780.57M | 757.07M | 707.01M |
| Cost of Revenue | 85.27M | 86.25M | 86.93M | 89.55M | 88.30M |
| Gross Profit | 722.93M | 710.08M | 693.64M | 667.51M | 618.71M |
| SG&A Expenses | 322.98M | 291.27M | 281.34M | 273.32M | 249.84M |
| Depreciation & Amortization | 229.37M | 221.89M | 221.89M | 221.89M | 207.22M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 637.63M | 599.41M | 590.16M | 584.77M | 545.36M |
| Operating Income | 170.58M | 196.92M | 190.40M | 172.30M | 161.65M |
| Income Before Tax | 77.68M | 108.24M | 92.62M | 80.85M | 53.00M |
| Income Tax Expenses | 29.77M | 33.29M | 29.75M | 22.41M | 16.73M |
| Earnings from Continuing Operations | 47.92 | 74.95 | 62.87 | 58.44 | 36.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.92M | 74.95M | 62.87M | 58.44M | 36.27M |
| EBIT | 170.58M | 196.92M | 190.40M | 172.30M | 161.65M |
| EBITDA | 404.19M | 422.37M | 416.48M | 398.49M | 373.08M |
| EPS Basic | 1.52 | 2.36 | 1.99 | 1.84 | 1.13 |
| Normalized Basic EPS | 2.11 | 2.61 | 2.36 | 1.89 | 1.73 |
| EPS Diluted | 0.87 | 1.68 | 1.71 | 1.60 | 1.03 |
| Normalized Diluted EPS | 1.66 | 2.08 | 1.90 | 1.54 | 1.41 |
| Average Basic Shares Outstanding | 127.77M | 127.12M | 126.83M | 127.25M | 127.94M |
| Average Diluted Shares Outstanding | 152.04M | 158.66M | 151.43M | 151.47M | 152.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |